Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

pharm 2 > anti DM tables > Flashcards

anti DM tables Flashcards

1
Q

Biguanides

A

metformin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Biguanides Moa

A

Liver (primary) – decreases glucose production
Muscle/adipose tissue - decreases insulin resistance

metoformin moa

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Metformin comments

 risk hypoglycemia?
 Weight ?
 first line??
 role with insulin?
 Beneficial in the treatment of?
 vitamin deficiency risk?
 ADRs common in what system
 metabolic adr? rare in?

A

 Low risk of hypoglycemia when used as monotherapy
 Weight neutral
 One of the first line drug therapy options added to diet and exercise
 Ameliorates insulin- associated weight gain
 Beneficial in the treatment of prediabetes
 B12 deficiency risk
 GI ADRs (e.g., diarrhea, nausea, cramping)
 Lactic acidosis (rare) in patients with cardiovascular, renal, or hepatic dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Glucagon-like peptide-receptor agonists (GLP1-RA)

A

dulaglutide
exenatide
liraglutide
lixisenatide
semaglutide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Glucagon-like peptide-receptor agonists (GLP1-RA) moa

A

incretin mimetic – Glucagon-like peptide 1 (GLP-1) receptor agonist that enhances glucose- dependent insulin secretion by the pancreatic beta-cell, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

dulaglutide moa

A

incretin mimetic – Glucagon-like peptide 1 (GLP-1) receptor agonist that enhances glucose- dependent insulin secretion by the pancreatic beta-cell, suppresses
inappropriately elevated glucagon secretion, and slows gastric emptying

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

exenatide moa

A

incretin mimetic – Glucagon-like peptide 1 (GLP-1) receptor agonist that enhances glucose- dependent insulin secretion by the pancreatic beta-cell, suppresses
inappropriately elevated glucagon secretion, and slows gastric emptying

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

liraglutide moa

A

incretin mimetic – Glucagon-like peptide 1 (GLP-1) receptor agonist that enhances glucose- dependent insulin secretion by the pancreatic beta-cell, suppresses
inappropriately elevated glucagon secretion, and slows gastric emptying

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

lixisenatide moa

A

incretin mimetic – Glucagon-like peptide 1 (GLP-1) receptor agonist that enhances glucose- dependent insulin secretion by the pancreatic beta-cell, suppresses
inappropriately elevated glucagon secretion, and slows gastric emptying

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

semaglutide moa

A

incretin mimetic – Glucagon-like peptide 1 (GLP-1) receptor agonist that enhances glucose- dependent insulin secretion by the pancreatic beta-cell, suppresses
inappropriately elevated glucagon secretion, and slows gastric emptying

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Glucagon-like peptide-receptor agonists (GLP1- RA)

 risk of hypoglycemia
 nausea?
 Weight?
 CV/ renal? agents?
 Injection site?
 Pancreatitis (rare)
 May be associated with dx of what GI organ?
 Risk of tumors where?

A

 Low risk of hypoglycemia when used as monotherapy
 Nausea
 Weight loss
 CV benefit (albiglutide, dulaglutide, liraglutide, semaglutide) and renal
benefit (liraglutide, semaglutide)
 Injection site reactions
 Pancreatitis (rare)
 May be associated with gallbladder disease
 Risk of Thyroid-C cell tumors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Glucagon-like, peptide-1 (GLP-1) agonist and glucose- dependent insulinotropic polypeptide (GIP) agonist (a “twincretin”):

A

tirzepatide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Glucagon-like, peptide-1 (GLP-1) agonist and glucose- dependent insulinotropic polypeptide (GIP) agonist moa

A

increases insulin secretion in response to elevated glucose, decreases glucagon
secretion, slows gastric emptying

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

tirzepatide moa

A

increases insulin secretion in response to elevated glucose, decreases glucagon
secretion, slows gastric emptying

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

tirzepatide

 risk of hypoglycemia?
 weight?
 A1c reduction?
 CV/renal?
 May delay absorption of?

A

 Low risk of hypoglycemia
 More weight loss than GLP-1 agonists
 More A1c reduction than most GLP-1 agonists.
 No CV or kidney outcomes data yet.
 May delay oral contraceptive absorption

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Sodium glucose cotransporter-2 inhibitors (SGLT-2

A

bexagliflozin
canagliflozin
dapagliflozin
empagliflozin
ertugliflozin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Sodium glucose cotransporter-2 inhibitors (SGLT-2) moa

A

Inhibition the protein, Sodium glucose cotransporter-2 in the proximal tubules, blocks
the reabsorption of glucose in the kidney, increases glucose excretion, and lowers
blood glucose levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

bexagliflozin moa

A

Inhibition the protein, Sodium glucose cotransporter-2 in the proximal tubules, blocks
the reabsorption of glucose in the kidney, increases glucose excretion, and lowers
blood glucose levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

canagliflozin moa

A

Inhibition the protein, Sodium glucose cotransporter-2 in the proximal tubules, blocks
the reabsorption of glucose in the kidney, increases glucose excretion, and lowers
blood glucose levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

dapagliflozin moa

A

Inhibition the protein, Sodium glucose cotransporter-2 in the proximal tubules, blocks
the reabsorption of glucose in the kidney, increases glucose excretion, and lowers
blood glucose levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

empagliflozin moa

A

Inhibition the protein, Sodium glucose cotransporter-2 in the proximal tubules, blocks
the reabsorption of glucose in the kidney, increases glucose excretion, and lowers
blood glucose levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

ertugliflozin moa

A

Inhibition the protein, Sodium glucose cotransporter-2 in the proximal tubules, blocks
the reabsorption of glucose in the kidney, increases glucose excretion, and lowers
blood glucose levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Sodium glucose cotransporter-2 inhibitors (SGLT-2)

risk of hypoglycemia?
 Weight?
 CV and renal? agents?
 Genital side effects?
 BP?
 lipid profile?
 urine?
 pancreas?
 May be associated with rare? agent?
 bones?
 Increased risk of what gangrene?

A

 Low risk of hypoglycemia
 Weight loss
 CV and renal benefit (canagliflozin, dapagliflozin, empagliflozin)
 Genital fungal (yeast) infections (male/female)
 UTI
 Dizziness, hypotension,
 Increased LDL
 Increased urination
 Acute pancreatitis (rare)
 May be associated with rare amputations (canagliflozin
 Increases fracture risk (rare)
 Increased risk of Fournier’s gangrene - infection in the scrotum (which includes the testicles), penis, or perineum (rare)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Dipeptidyl-
Peptidase-4
Inhibitors (DPP-4

A

alogliptin
linagliptin
saxagliptin
sitagliptin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

Dipeptidyl- Peptidase-4 Inhibitors (DPP-4 )moa

A

Inhibits the action of DPP- 4, an enzyme which destroys incretin hormones (Glucagon-like
peptide 1 (GLP-1 and Gastric inhibitory polypeptide GIP) The inhibition causes decreased glucagon release which results in increased insulin secretion, decreased gastric emptying and decreased blood glucose levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

alogliptin moa

A

Inhibits the action of DPP- 4, an enzyme which destroys incretin hormones (Glucagon-like
peptide 1 (GLP-1 and Gastric inhibitory polypeptide GIP) The inhibition causes decreased glucagon release which results in increased insulin secretion, decreased gastric emptying and decreased blood glucose levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

linagliptin moa

A

Inhibits the action of DPP- 4, an enzyme which destroys incretin hormones (Glucagon-like
peptide 1 (GLP-1 and Gastric inhibitory polypeptide GIP) The inhibition causes decreased glucagon release which results in increased insulin secretion, decreased gastric emptying and decreased blood glucose levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

saxagliptin moa

A

Inhibits the action of DPP- 4, an enzyme which destroys incretin hormones (Glucagon-like
peptide 1 (GLP-1 and Gastric inhibitory polypeptide GIP) The inhibition causes decreased glucagon release which results in increased insulin secretion, decreased gastric emptying and decreased blood glucose levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

sitagliptin moa

A

Inhibits the action of DPP- 4, an enzyme which destroys incretin hormones (Glucagon-like
peptide 1 (GLP-1 and Gastric inhibitory polypeptide GIP) The inhibition causes decreased glucagon release which results in increased insulin secretion, decreased gastric emptying and decreased blood glucose levels

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

DPP-4 inhibitors

 risk of hypoglycemia?
 Weight?
 May be associated with?
 CV?
 joints?

A

 Low risk of hypoglycemia when used as monotherapy
 Weight neutral
 May be associated with pancreatitis
 New or worsening heart failure
 May cause severe joint pain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

Thiazolidinedione
(TZD)

A

pioglitazone
rosiglitazone

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

TZD moa

A

Muscle and adipose – peroxisome proliferator- activated receptor γ(gamma) - (PPARγ) agonist, makes tissues more sensitive to endogenous insulin and enhances glucose uptake into the tissues. Does not increase pancreatic insulin secretion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

rosiglitazone moa

A

Muscle and adipose – peroxisome proliferator- activated receptor γ(gamma) - (PPARγ) agonist, makes tissues more sensitive to endogenous insulin and enhances glucose uptake into the tissues. Does not increase pancreatic insulin secretion

34
Q

pioglitazone moa

A

Muscle and adipose – peroxisome proliferator- activated receptor γ(gamma) - (PPARγ) agonist, makes tissues more sensitive to endogenous insulin and enhances glucose uptake into the tissues. Does not increase pancreatic insulin secretion

35
Q

Thiazolidinedione

 risk of hypoglycemia?
 peripheral tissues?
 Weight ?
 CV?
bones?

A

 Low risk of hypoglycemia when used as monotherapy
 Edema
 Weight gain
 Heart failure. Avoid in patient with symptomatic heart failure
 Increased fracture risk

36
Q

Sulfonylureas (SU)

Note: 1st generation not included since not commonly used in practice

A

glimepiride (2nd Gen)
glipizide (2nd Gen)
glyburide(2nd Gen)

Start with ”g” and end in “ide” - glipizide, glyburide, glimepiride

37
Q

Sulfonylureas (SU) moa

A

Secretagogue
Pancreas - Stimulates beta cells causing insulin secretion

38
Q

glimepiride moa

A

Secretagogue
Pancreas - Stimulates beta cells causing insulin secretion

39
Q

glipizide moa

A

Secretagogue
Pancreas - Stimulates beta cells causing insulin secretion

40
Q

glyburide moa

A

Secretagogue
Pancreas - Stimulates beta cells causing insulin secretion

41
Q

Sulfonylureas (SU)

 Hypoglycemia?
 Weight?
 “Durability”

A

 Hypoglycemia, especially with renal dysfunction (usually discontinue with use of insulin)
 Weight gain
 “Durability” declines over time

42
Q

metformin

A

Biguanides

43
Q

Liver (primary) – decreases glucose production
Muscle/adipose tissue - decreases insulin resistance

A

Biguanides Moa

44
Q

dulaglutide
exenatide
liraglutide
lixisenatide
semaglutide

A

Glucagon-like peptide-receptor agonists (GLP1-RA)

45
Q

incretin mimetic – Glucagon-like peptide 1 (GLP-1) receptor agonist that enhances glucose- dependent insulin secretion by the pancreatic beta-cell, suppresses
inappropriately elevated glucagon secretion, and slows gastric emptying

A

Glucagon-like peptide-receptor agonists (GLP1-RA) moa

46
Q

tirzepatide

A

Glucagon-like, peptide-1 (GLP-1) agonist and glucose- dependent insulinotropic polypeptide (GIP) agonist (a “twincretin”):

47
Q

increases insulin secretion in response to elevated glucose, decreases glucagon
secretion, slows gastric emptying

A

Glucagon-like, peptide-1 (GLP-1) agonist and glucose- dependent insulinotropic polypeptide (GIP) agonist moa

48
Q

bexagliflozin
canagliflozin
dapagliflozin
empagliflozin
ertugliflozin

A

Sodium glucose cotransporter-2 inhibitors (SGLT-2

49
Q

Inhibition the protein, Sodium glucose cotransporter-2 in the proximal tubules, blocks
the reabsorption of glucose in the kidney, increases glucose excretion, and lowers
blood glucose levels

A

Sodium glucose cotransporter-2 inhibitors (SGLT-2) moa

50
Q

alogliptin
linagliptin
saxagliptin
sitagliptin

A

Dipeptidyl-
Peptidase-4
Inhibitors (DPP-4

51
Q

Inhibits the action of DPP- 4, an enzyme which destroys incretin hormones (Glucagon-like
peptide 1 (GLP-1 and Gastric inhibitory polypeptide GIP) The inhibition causes decreased glucagon release which results in increased insulin secretion, decreased gastric emptying and decreased blood glucose levels

A

Dipeptidyl- Peptidase-4 Inhibitors (DPP-4 )moa

52
Q

pioglitazone
rosiglitazone

A

Thiazolidinedione
(TZD)

53
Q

Muscle and adipose – peroxisome proliferator- activated receptor γ(gamma) - (PPARγ) agonist, makes tissues more sensitive to endogenous insulin and enhances glucose uptake into the tissues. Does not increase pancreatic insulin secretion

54
Q

glimepiride
glipizide
glyburide

A

Sulfonylureas (SU)

Note: 1st generation not included since not commonly used in practice

55
Q

Secretagogue
Pancreas - Stimulates beta cells causing insulin secretion

A

Sulfonylureas (SU) moa

56
Q

rapid acting insulins

A

Humalog,
Amelog,
Lyumjev (insulin lispro)
NovoLog,
Fiasp* (insulin aspart)
Apidra (insulin glulisine)

57
Q

use of rapid acting insulins

A

Bolus dosing(meals) and insulin
pumps (administration ranges 5-15
minutes before meals –see specific
product information)

58
Q

short acting insulins

A

Humulin R or Novolin R - Regular
insulin -

59
Q

use of short acting insulins

A

Bolus dosing(meals)
(administration ranges 15-30
minutes before meals –see specific
product information)

60
Q

intermeadiate acting insulins

A

Humulin N or Novolin N - NPH

61
Q

intermeadiate acting insulins use

A

~ “Basal-like” (administration Q
day to BID)

62
Q

long acting insulins

A

Lantus, Basaglar* Rezvoglar,
Semglee, (insulin glargine) – 100
units/mL

Toujeo (insulin glargine) – 300
unitls/mL

Levemir (insulin detemir) – to be
discontinued in 2024

63
Q

long acting insulin uses

A

Basal (administration Q day)

64
Q

ultra long acting insulins

A

Tresiba (insulin degludec)

65
Q

ultra long acting insulins use

A

Basal (administration Q day,
anytime of day)

66
Q

Humalog,
Amelog,
Lyumjev (insulin lispro)
NovoLog,
Fiasp* (insulin aspart)
Apidra (insulin glulisine)

A

rapid acting insulins

67
Q

Bolus dosing(meals) and insulin
pumps (administration ranges 5-15
minutes before meals –see specific
product information)

A

use of rapid acting insulins

68
Q

Humulin R or Novolin R - Regular
insulin -

A

short acting insulins

69
Q

Bolus dosing(meals)
(administration ranges 15-30
minutes before meals –see specific
product information)

A

use of short acting insulins

70
Q

Humulin N or Novolin N - NPH

A

intermeadiate acting insulins

71
Q

~ “Basal-like” (administration Q
day to BID)

A

intermeadiate acting insulins use

72
Q

Lantus, Basaglar* Rezvoglar,
Semglee, (insulin glargine) – 100
units/mL

Toujeo (insulin glargine) – 300
unitls/mL

Levemir (insulin detemir) – to be
discontinued in 2024

A

long acting insulins

73
Q

Basal (administration Q day)

A

long acting insulin uses

74
Q

Tresiba (insulin degludec)

A

ultra long acting insulins

75
Q

Basal (administration Q day,
anytime of day)

A

ultra long acting insulins use

ultra long lasting insulin

76
Q

which DM rx have CV benefits

A

GLP-RA and SGLT-2 inhib

77
Q

which DM rx have renal benefits

A

SGLT-2 inhib

78
Q

which DM rx have risk of hypoglycemia

A

SU and insulins

79
Q

which DM Rx cause weight gain

A

SU and TZD

80
Q

which DM Rx cause weight loss

A

SGLT2 inhib
trizepatide
GLP1RA

81
Q

which DM rx can cause new/worse HF

A

DPP4 inhib and TZD

pharm 2 (20 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions